Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)

CHAPTER 1

SUBJECT MATTER AND DEFINITIONS

- Article 1 Subject matter
- Article 2 Definitions

CHAPTER 2

MARKETING AUTHORISATION REQUIREMENTS

- Article 3 Donation, procurement and testing
- Article 4 Clinical trials
- Article 5 Good manufacturing practice
- Article 6 Issues specific to medical devices
- Article 7 Specific requirements for advanced therapy medicinal products containing devices

CHAPTER 3

MARKETING AUTHORISATION PROCEDURE

- Article 8 Evaluation procedure
- Article 9 Combined advanced therapy medicinal products

CHAPTER 4

SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET

- Article 10 Summary of product characteristics
- Article 11 Labelling of outer/immediate packaging
- Article 12 Special immediate packaging
- Article 13 Package leaflet

CHAPTER 5

POST-AUTHORISATION REQUIREMENTS

- Article 14 Post-authorisation follow-up of efficacy and adverse reactions, and risk management
- Article 15 Traceability

CHAPTER 6

INCENTIVES

- Article 16 Scientific advice
- Article 17 Scientific recommendation on advanced therapy classification
- Article 18 Certification of quality and non-clinical data
- Article 19 Reduction of the fee for marketing authorisation

CHAPTER 7

COMMITTEE FOR ADVANCED THERAPIES

- Article 20 Committee for Advanced Therapies
- Article 21 Composition of the Committee for Advanced Therapies
- Article 22 Conflicts of interest
- Article 23 Tasks of the Committee for Advanced Therapies

CHAPTER 8

GENERAL AND FINAL PROVISIONS

- Article 24 Amendments to the Annexes
- Article 25 Report and review
- Article 25a Exercise of the delegation
- Article 26 Committee procedure
- Article 27 Amendments to Regulation (EC) No 726/2004
- Article 28 Amendments to Directive 2001/83/EC
- Article 29 Transitional period
- Article 30 Entry into force
 - Signature

ANNEX I

Manipulations referred to in the first indent of Article 2(1)(c)

cutting, grinding, shaping, centrifugation, soaking in antibiotic or antimicrobial solutions,...

ANNEX II

Summary of product characteristics referred to in Article 10

- 1. Name of the medicinal product.
- 2. Composition of the product:
 - 2.1. general description of the product, if necessary with explanatory drawings...
 - 2.2. qualitative and quantitative composition in terms of the active substances...
- 3. Pharmaceutical form.

- 4. Clinical particulars:
 - 4.1. therapeutic indications,
 - 4.2. posology and detailed instructions for use, application, implantation or administration...
 - 4.3. contra-indications,
 - 4.4. special warnings and precautions for use, including any special precautions...
 - 4.5. interaction with other medicinal products and other forms of interactions,...
 - 4.6. use during pregnancy and lactation,
 - 4.7. effects on ability to drive and to use machines,
 - 4.8. undesirable effects,
 - 4.9. overdose (symptoms, emergency procedures).
- 5. Pharmacological properties:
 - 5.1. pharmacodynamic properties,
 - 5.2. pharmacokinetic properties,
 - 5.3. preclinical safety data.
- 6. Quality particulars:
 - 6.1. list of excipients, including preservative systems,
 - 6.2. incompatibilities,
 - 6.3. shelf life, when necessary after reconstitution of the medicinal product...
 - 6.4. special precautions for storage,
 - 6.5. nature and contents of container and special equipment for use,...
 - 6.6. special precautions and instructions for handling and disposal of a...
- 7. Marketing authorisation holder.
- 8. Marketing authorisation number(s).
- 9. Date of the first authorisation or renewal of the authorisation....
- 10. Date of revision of the text.

ANNEX III

Labelling of outer/immediate packaging referred to in Article 11

The name of the medicinal product and, if appropriate, an...

ANNEX IV

Package leaflet referred to in Article 13

For the identification of the advanced therapy medicinal product: the...

Changes to legislation: There are outstanding changes not yet made to Regulation (EC) No 1394/2007 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

- (1) OJ C 309, 16.12.2006, p. 15.
- (2) Opinion of the European Parliament of 25 April 2007 (not yet published in the Official Journal) and Council Decision of 30 October 2007.
- (3) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Regulation (EC) No 1901/2006 (OJ L 378, 27.12.2006, p. 1).
- (4) OJ L 136, 30.4.2004, p. 1. Regulation as amended by Regulation (EC) No 1901/2006.
- (5) OJ L 102, 7.4.2004, p. 48.
- (6) OJ L 121, 1.5.2001, p. 34. Directive as amended by Regulation (EC) No 1901/2006.
- (7) OJ L 91, 9.4.2005, p. 13.
- (8) OJ L 262, 14.10.2003, p. 22.
- (9) OJ L 169, 12.7.1993, p. 1. Directive as last amended by Directive 2007/47/EC of the European Parliament and of the Council (OJ L 247, 21.9.2007, p. 21).
- (10) OJ L 189, 20.7.1990, p. 17. Directive as last amended by Directive 2007/47/EC.
- (11) OJ L 33, 8.2.2003, p. 30.
- (12) OJ L 281, 23.11.1995, p. 31. Directive as amended by Regulation (EC) No 1882/2003 (OJ L 284, 31.10.2003, p. 1).
- (13) OJ L 184, 17.7.1999, p. 23. Decision as amended by Decision 2006/512/EC (OJ L 200, 22.7.2006, p. 11).

Changes to legislation:

_

There are outstanding changes not yet made to Regulation (EC) No 1394/2007 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. View outstanding changes

Changes and effects yet to be applied to :

Regulation revoked in part by S.I. 2019/775 Sch. 9 para. 1(o)